Evaluation of CAR-T Cells' Cytotoxicity against Modified Solid Tumor Cell Lines

In recent years, adoptive cell therapy has gained a new perspective of application due to the development of technologies and the successful clinical use of CAR-T cells for the treatment of patients with malignant B-cell neoplasms. However, the efficacy of CAR-T therapy against solid tumor remains a...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2023-02, Vol.11 (2), p.626
Main Authors: Valiullina, Aigul Kh, Zmievskaya, Ekaterina A, Ganeeva, Irina A, Zhuravleva, Margarita N, Garanina, Ekaterina E, Rizvanov, Albert A, Petukhov, Alexey V, Bulatov, Emil R
Format: Article
Language:English
Subjects:
Adenocarcinoma
Antigens
Biosensors
Breast cancer
Breast carcinoma
Cancer
CAR-T
Carcinoma
CD19 antigen
Cell culture
Cell therapy
chemokine
cytokine
Cytokines
Cytotoxicity
Drug therapy
Efficiency
Inflammation
Lymphocytes
Lymphocytes B
Lymphocytes T
Patient outcomes
Prostate
Prostate carcinoma
Red fluorescent protein
solid tumor
Solid tumors
Tumor cell lines
Tumor cells
tumor model
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, adoptive cell therapy has gained a new perspective of application due to the development of technologies and the successful clinical use of CAR-T cells for the treatment of patients with malignant B-cell neoplasms. However, the efficacy of CAR-T therapy against solid tumor remains a major scientific and clinical challenge. In this work, we evaluated the cytotoxicity of 2nd generation CAR-T cells against modified solid tumors cell lines-lung adenocarcinoma cell line H522, prostate carcinoma PC-3M, breast carcinoma MDA-MB-231, and epidermoid carcinoma A431 cell lines transduced with lentiviruses encoding red fluorescent protein Katushka2S and the CD19 antigen. A correlation was demonstrated between an increase in the secretion of proinflammatory cytokines and a decrease in the confluence of tumor cells' monolayer. The proposed approach can potentially be applied to preliminarily assess CAR-T cell efficacy for the treatment of solid tumors and estimate the risks of developing cytokine release syndrome.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines11020626